1.97
0.01 (0.51%)
0.01 (0.51%)
Upgrade to Real-Time
Regular Market
| Volume | 69 |
|
|||||
| News | - | ||||||
| Day High | 1.97 | Low High |
|||||
| Day Low | 1.88 | ||||||
Best deals to access real time data! |
|
CHART Trader
Monthly Subscription
for only
|
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Larimar Therapeutics Inc | LRMR | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
 |
|
|---|---|---|---|---|
| 0.01 | 0.51% | 1.97 | 09:30:55 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.97 | 1.88 | 1.97 | 1.96 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 9 | 69 | - | 1.90 - 15.2581 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 09:30:35 | 4 | $ 2.10 | USD |
Period:
Draw Mode:
Larimar Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 34.89M | 17.71M | 11.25M | $ - | $ - | -2.94 | -0.80 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 101.50k | 1.20% |
Larimar Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical LRMR Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.13 | 2.35 | 1.95 | 2.05 | 26,264 | -0.16 | -7.51% |
| 1 Month | 2.63 | 2.69 | 1.90 | 2.17 | 15,605 | -0.66 | -25.1% |
| 3 Months | 3.86 | 4.20 | 1.90 | 3.03 | 35,493 | -1.89 | -48.96% |
| 6 Months | 10.90 | 11.05 | 1.90 | 4.31 | 128,265 | -8.93 | -81.93% |
| 1 Year | 9.40 | 15.2581 | 1.90 | 6.76 | 96,993 | -7.43 | -79.04% |
| 3 Years | 12.00 | 25.87 | 1.90 | 9.99 | 89,568 | -10.03 | -83.58% |
| 5 Years | 12.00 | 25.87 | 1.90 | 9.99 | 89,568 | -10.03 | -83.58% |
Larimar Therapeutics Description
| Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia. |